Oxford Biomedica Joins COVID-19 Vaccine Consortium
Oxford Biomedica has joined a consortium to rapidly develop a potential vaccine candidate for COVID-19 that is expected to be the UK’s first COVID-19 vaccine into clinical trials later this month.
The vaccine candidate uses adenoviral-vector technology developed at the Jenner Institute in Oxford. ChAdOx1 has been shown to generate a strong immune response from just one dose.
The consortium is led by the Jenner Institute at Oxford University and includes the Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics and Halix.